1. There are limited data about the vaccines for people who have had covid. But we can learn from the @Pfizer@BioNTech and @moderna trials which had 3% and 2.2% participants respectively confirmed at baseline (via FDA briefing docs)
2. In the Pfizer trial there were 9 reinfections among 670 participants (1.3%) who received placebo which was the same rate as those without prior infection (259 of 19,818 participants, 1.3%).
Only 1 reinfection in the vaccine group (after ≥ 7 days) for those w/ prior infection
3. We need to learn more about this with so many people with prior infections getting vaccinated. But this finding suggests vaccine-induced immune response may add protection to the natural response and adds another layer to the superhuman concept 👇
Why 2 proline (P) substitutions will go down in history.
Introducing 2P's at the beginning of the central helix (CH) stabilized the spike protein's confirmation upon entering cells.
From the Jan 10 #SARSCoV2 sequence, this 2P Δ was incorporated into the mRNA vaccine designs /1
The United States has an ambitious plan to get to population level immunity, but it doesn't have the vaccines to accomplish it (no less the buy in of Americans)
@WSJgraphic by @ErikBrynildsen@joshulick@TaylorUmlauf @toddlindeman /1
Before the vaccine problems with Sanofi-GSK (wrong dose) and Astra Zeneca/Oxford (? dose) the US was already short in covering its population nature.com/articles/d4158… /2
We have the FDA (VRBPAC) external view 77% affirmative vote.
Not sure what the 18% who voted no or 5% abstaining were thinking.
But expect final FDA EUA approval for the 1st vaccine for the US in a very short time. 👍👍👏👏
The "no" concerns about age 16-17 are not consistent with the protocol inclusion criteria, even though the number of participants < 18 were low.
The number of participants by age, 95 were age 16 or 17